By the Top Tier Newswire AI Desk · October 16, 2026 at 11:15 AM ET · reviewed against 13 wire stories
MODERNA INC (MRNA) is down -9.01% in the latest session. Our newswire has captured 13 stories on MRNA across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Moderna Inc (NASDAQ: MRNA) shares fell 9.01% to $215.20, marking a sharp reversal after a recent surge. The primary driver is profit taking following a significant rally driven by anticipation for upcoming cancer vaccine data.
What Happened
The stock gave back part of its recent gains as investors locked in profits. Shares had reached their highest close in a year on October 15, 2026, ending that session at $236.50. Over the past three months, the stock gained 282.6%, significantly outpacing the 4.1% return of the S&P 500. The selling pressure hit one of biotech’s hottest trades, with the stock that ran the furthest facing the heaviest selling. Ahead of the drop, Goldman Sachs analyst Salveen Richter raised the firm’s price target on Moderna to $137 from $120 while maintaining a Neutral rating. Investors are looking ahead to an October 24 presentation of detailed cancer trial results for a melanoma vaccine partnered with Merck.
What The Data Shows
Intraday trading showed a volatile session. The stock opened at $235.90 and hit a session high of $237.96 at 9:30 AM ET. It then dropped to a session low of $208.92 at 10:10 AM ET before closing at $215.20. Volume so far stands at 8.6 million shares, which is 0.5 times the 3-month daily average. The company remains unprofitable with a trailing twelve-month EPS of -8.01 and revenue down 27.6%. The market cap is $90.3 billion. Over the last 8 sessions, the stock moved up 27.0%, rising from $187.46 to $238.14. The 52-week range is $22.28 to $242.29. Unusual options activity included 29 notable prints, with call premium of $25.0 million versus put premium of $8.7 million. The largest single print was $4.8 million. Recent insider filings show 4 sells totaling $45.6 million in the last 90 days, with no buys.
What To Watch
Investors are focused on the scheduled October 24 presentation of detailed cancer trial results. This catalyst is central to the current valuation and sentiment surrounding the stock.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
MRNA · today's session (5-min) · -9.01% vs prior close · updated 11:15 AM ETAI sentiment, last 36h · averaged over 13 stories · 56/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
6h ago24/7 Wall St.BEARISH 38General
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA) stock is down 10% to $214.03 in morning trading, giving back part of a steep run tied to its personalized cancer vaccine. Meanwhile, BioNTech SE (NASDAQ:BNTX) stock is down 2% to […]
6h agoYahoo FinanceBEARISH 44General
What Is The Case For Waiting On Moderna Stock?
Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares reached their highest close in a year on October 15, 2026, ending the session at $236.50. Investors paying that premium are betting the drugmaker is ready to grow again. To meet those expectations, its sales, nearly all from COVID vaccines, have to stop shrinking, while its newer vaccines and cancer drugs have to start selling. Has the business caught up with Moderna's share pri
6h agoInvesting.com MarketsBEARISH 38General
Why is Moderna stock dropping today?
Why is Moderna stock dropping today?
6h agoMarketChameleonBULLISH 58General
MRNA Iron Condor Spread Can Make 78% in Next 10 Days
Take a deep dive into some of Market Chameleon's most relevant trade ideas. This article includes detailed breakdowns of strategies and payout diagrams for MRNA from October 16, 2026.
17h agoStocktwits NewsBULLISH 67General
Why Did MRNA, KO, V Stocks Climb To 52-Week Highs Today?
Moderna’s upcoming cancer vaccine data, Coca-Cola’s new KFC beverage partnership and Visa’s expanding services business stoked investor interest.
1d agoTipRanksBULLISH 64Product/PR
Moderna Stock Jumps 4.5% as Major Cancer Vaccine Catalyst Approaches
Shares of vaccine maker Moderna ($MRNA) rose by about 4.5% in Thursday trading as investors looked ahead to an October 24 presentation of detailed cancer trial resu...
1d agoStocktwits NewsBULLISH 63Analyst
MRNA Stock Hits Fresh 52-Week Highs As Goldman Raises Target Ahead Of Melanoma Data
Goldman Sachs analyst Salveen Richter raised the firm’s price target on Moderna to $137 from $120 while maintaining a Neutral rating.
1d agoSeeking AlphaBULLISH 63Product/PR
Moderna rallies despite bearish views ahead of cancer vaccine data
Moderna (MRNA) stock rallies despite bearish views from analysts ahead of new late-stage trial data for Merck (MRK)-partnered melanoma cancer vaccine. Read more here.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →